Literature DB >> 2949270

[Mechanism of enzymatic resistance to beta-lactam antibiotics].

A Philippon, G Paul, P Nevot.   

Abstract

The resistance of bacteria, particularly Gram-negative bacteria, to beta-lactam antibiotics is principally caused by enzymes. Beta-lactamases inactivate these antibiotics by opening, more or less rapidly, the beta-lactam ring. The chronology of therapeutic discoveries is governed by natural and acquired resistance. The first step was to establish the characteristics of beta-lactamases (location, biogenesis, enzymatic profile, affinity constant, inhibition profile, isoelectric point, molecular weight, genetic determination, etc.). Advances in the selection of natural or semi-synthetic compound are centred on the following points: increased stability to beta-lactamases, inhibitory effect, reduced inducibility, low affinity for the enzyme, greater speed of penetration through the bacterial wall, increased tropism for targets. Notable among the new beta-lactam antibiotics are acylureidopenicillins, beta-lactamase inhibitors and carbapenems. The antibacterial activity of third generation cephalosporins is 10 to 1000 times higher than that of previous cephalosporins; the result is a wider spectrum including, in particular, cephalosporinase-producing organisms. Concerning acquired resistance, the behaviour of new antibiotics must be examined by comparing the minimum inhibitory concentrations of isogeneic and clinical strains, and according to phenotype or mechanism: sensitive, penicillinase producer, cephalosporinase producer or producer of both penicillinases and cephalosporinases. During synthesis of a penicillinase, penicillins and some cephalosporins are more or less inactivated. With a constitutive cephalosporinase, all cephalosporins are inactivated as are, to a lesser degree, penicillins and monobactams, e.g. aztreonam. The emergence of new enzymes, including broad-spectrum beta-lactamases, and their extension to sensitive bacteria show that the enzymatic mechanism still has potentials for development.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2949270

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  3 in total

1.  Cloning and expression of the ponB gene, encoding penicillin-binding protein 1B of Escherichia coli, in heterologous systems.

Authors:  J Plá; F Rojo; M A de Pedro; J A Ayala
Journal:  J Bacteriol       Date:  1990-08       Impact factor: 3.490

Review 2.  Beta-lactamases in clinical isolates. Spectrum implications of sulbactam/ampicillin.

Authors:  J F Acar; L Gutmann; M D Kitzis
Journal:  Drugs       Date:  1988       Impact factor: 9.546

3.  Emergence of clinical isolates of Escherichia coli producing TEM-1 derivatives or an OXA-1 beta-lactamase conferring resistance to beta-lactamase inhibitors.

Authors:  X Y Zhou; F Bordon; D Sirot; M D Kitzis; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.